SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Read more breaking news

 

 

South Korean CRO adopts Instem tech to automate data collection

Melissa Fassbender

By Melissa Fassbender

12-Jul-2017

Chemon offers a range of testing services including toxicity and efficacy, pharmacokinetics, and in vitro pharmacology (Image: iStock/jmccurley51)
Chemon offers a range of testing services including toxicity and efficacy, pharmacokinetics, and in vitro pharmacology (Image: iStock/jmccurley51)

Chemon Inc. is automating its preclinical data collection process with Instem’s software solutions and services.

Chemon Inc. is a privately owned, non-clinical contract research organization (CRO) headquartered in Suwon, South Korea with a certified research laboratory in Yongin.

Julie Jones, a company representative at the UK-based IT solutions company, Instem, told us Chemon is currently collecting their preclinical study data using a combination of manual processes (i.e. collecting data on paper) and Excel.

This is very labor intensive as the data then needs to be transcribed from the paper forms into Excel and it is also more prone to transcription errors,” she said.

To automate this process at its laboratory in Yongin, ChemOn purchased Instem’s Provantis preclinical data management solution as well as its submit software suite for creating and managing SEND-compliant datasets.

Chemon will no longer need to manually create study reports and will be able to provide study reports to the regulators and their clients in a more timely manner,” said Jones.

SEND compliant

SEND (Standard for Exchange of Nonclinical Data) is an implementation of the CDISC Standard Data Tabulation Model (SDTM), which specifies a way to present nonclinical data in a consistent file format, as well as variables and standardized scientific terminology.

As Jones noted, the SEND initiative is having “a big impact” on the pharma R&D community.

The mandate, which requires all datasets from studies supporting new drug applications, biologics license applications, and abbreviated new drug applications to be submitted in SEND format, went into effect December 2016. 

Related suppliers

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...